Who are losartan and HCTZ's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Micardis plus 80/12.5, olmesartan medoxomil + hydrochlorothiazide, if necessary, Fimasartan; Hydrochlorothiazide, Candesartan+HCTZ - Phase 1, Candesartan plus Hydrochlorothiazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/losartan-and-hctz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

losartan and HCTZ — Competitive Intelligence Brief

losartan and HCTZ (losartan and HCTZ) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + thiazide diuretic combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker + thiazide diuretic combination AT1 receptor (losartan); sodium-chloride cotransporter (HCTZ) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

losartan and HCTZ (losartan and HCTZ) — InVasc Therapeutics, Inc.. Losartan blocks angiotensin II receptors to relax blood vessels, while HCTZ increases sodium and water excretion to reduce blood volume, together lowering blood pressure.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
losartan and HCTZ TARGET	losartan and HCTZ	InVasc Therapeutics, Inc.	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (losartan); sodium-chloride cotransporter (HCTZ)
Micardis plus 80/12.5	Micardis plus 80/12.5	Heart Care Foundation	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
olmesartan medoxomil + hydrochlorothiazide, if necessary	olmesartan medoxomil + hydrochlorothiazide, if necessary	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Fimasartan; Hydrochlorothiazide	Fimasartan; Hydrochlorothiazide	Stendhal Americas, S.A.	phase 3	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (fimasartan); sodium-chloride cotransporter (hydrochlorothiazide)
Candesartan+HCTZ - Phase 1	Candesartan+HCTZ - Phase 1	Novartis	phase 3	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
Candesartan plus Hydrochlorothiazide	Candesartan plus Hydrochlorothiazide	Novartis	phase 3	Angiotensin II receptor blocker + Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + thiazide diuretic combination class)

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Heart Care Foundation · 1 drug in this class
InVasc Therapeutics, Inc. · 1 drug in this class
Novartis · 1 drug in this class
Stendhal Americas, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). losartan and HCTZ — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-and-hctz. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab